21 CFR Part 11 for researchers in Spain

When 21 CFR Part 11 applies to a Spanish study, interaction with EudraLex Annex 11, and Trialinx coverage.

Context in Spain

In Spain, trials regulated by AEMPS and ethics committees follow European regulation. Annex 11 of EudraLex (Vol. 4) is the European equivalent of 21 CFR Part 11 for GxP electronic records. Technical requirements are essentially equivalent.

Part 11 applies explicitly when the study is submitted to the FDA (for US approval or because the sponsor is US-based). A Europe-only study can meet Annex 11 without invoking Part 11, but if your EDC meets Part 11 you meet both.

Relevant scenarios

•Study submitted to the FDA for US approval
•US-based sponsor with contractual Part 11 requirement
•Multinational trial with at least one US site
•Device/product with parallel FDA regulatory approval

Part 11 (and Annex 11) coverage

✓Append-only audit trail with 7 datapoints (§11.10(e) + Annex 11 cl. 9)
✓System validation documentation available on Institutional (§11.10(a))
✓Readable export in CSV/JSON (§11.10(b))
✓Record protection with indefinite retention (§11.10(c))
✓Limited access with granular RBAC (§11.10(d))
✓Dual-component electronic signature (password + 2FA) (§11.200)

FAQ

Do I need Part 11 validation if I only submit to AEMPS?

Technically Part 11 is FDA, not AEMPS. But Annex 11 (European equivalent) has the same requirements. An EDC meeting Part 11 meets Annex 11 automatically.

Does Trialinx include a validation package?

On the Institutional plan, yes. Includes software IQ/OQ/PQ docs, change log, and quality controls.

Need specific documentation?

Contact